0001213900-24-081199 | 6-K | XBRL Viewer | Altamira Therapeutics LTD

Finance Income and Finance Expense (Details) - Schedule of Finance Income and Finance Expense - USD ($)	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Schedule of Finance Income and Finance Expense [Abstract]
Gain on modification of financial instruments		$ 40,331

Document And Entity Information	6 Months Ended
Document And Entity Information	Jun. 30, 2024
Document Information Line Items
Entity Registrant Name	Altamira Therapeutics Ltd.
Document Type	6-K
Current Fiscal Year End Date	--12-31
Amendment Flag	false
Entity Central Index Key	0001601936
Document Period End Date	Jun. 30, 2024
Document Fiscal Year Focus	2024
Document Fiscal Period Focus	Q2
Entity File Number	001-36582

Capital and Reserves (Details) - Schedule of Issued Share Capital - USD ($)	6 Months Ended
	Jun. 30, 2024	Dec. 31, 2023
Schedule of Issued Share Capital [Abstract]
Number, Common shares par value	2,670,524	1,447,785
USD, Common shares par value	$ 5,341	$ 2,956

Loans (Details) - CHF (SFr)								6 Months Ended
Loans (Details) - CHF (SFr)	Dec. 15, 2023	Jul. 10, 2023	May 01, 2023	Apr. 13, 2023	Dec. 28, 2022	Dec. 05, 2022	Sep. 09, 2022	Jun. 30, 2024	Jun. 30, 2023	Jul. 31, 2023
Loans [Line Items]
Loan amount (in Shares)			2,500,000
Loan bears interest rate			10.00%
Conversion per share			SFr 28.4
Aggregate of common shares (in Shares)			81,274	271,051		555,279			17,500
Exercise price per share			SFr 30.76
Issuance term			5 years				5 years
Purchase of warrants (in Shares)	81,274	555,556			2,359		2,085
Warrant exercise share					SFr 89.02		SFr 144
Common per share										SFr 17.62
Convertible loan agreement amount (in Francs)							SFr 600,000
Conversion price per share							SFr 22.4
Trading percentage							120.00%
Weighted average price percentage							90.00%
CHF [Member]
Loans [Line Items]
Aggregate of common shares (in Shares)								443,294
Aggregate cash payments (in Shares)								387,045
Conversion price per share							SFr 17.62

Capital and Reserves (Details) - Schedule of Common Share - shares	6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Schedule of Common Share [Line Items]
2022 Commitment Purchase Agreement	555,279	17,500
HCW Sales Agreement	637,460	104,147
Conversion convertible loan		217,050

Label

Element

Value

ears_FairValueOfStockOptionsGranted

$ 49,622

ears_FairValueOfWarrantsIssued

4,660,305

ears_FairValueOfWarrantsIssued

196,127